



25 AUG 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Mark Chao, PhD, JD
Intellectual Property Department
TAKEDA PHARMACEUTICALS NORTH AMERICA
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069

In re Application of:	:	
WATANABE, Tatsuya, et al.	:	
U.S. Application No.: 10/518,184	:	DECISION ON PETITION FOR
PCT No.: PCT/JP03/07741	:	REVIVAL OF ABANDONED
International Filing Date: 18 June 2003	:	APPLICATION UNDER
Priority Date: 19 June 2002	:	37 CFR 1.137(b)
Attorney's Docket No.: 3057 USOP	:	
For: PREVENTIVES/REMEDIES FOR	:	
BONE AND JOINT DISEASE	:	

The petition for revival under 37 CFR 1.137(b) filed 12 August 2005 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "the entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional" meets the requirements of 37 CFR 1.137(b)(3).

Applicant has authorized a charge to Deposit Account No. 50-0799 for the basic national fee and the petition fee, and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application is granted as to the national stage in the United States of America.

It is noted that the original national stage papers filed 16 December 2004 included an executed declaration in compliance with 37 CFR 1.497.

This application is being returned to the National Stage Processing Division of the Office of PCT Operations for further processing in accordance with this decision. The date under 35 U.S.C. 371(c)(1), (c)(2), and (c)(4) is 12 August 2005.

Richard M. Ross
PCT Petitions Attorney
Office Of PCT Legal Administration
Telephone: (571) 272-3296
Facsimile: (571) 273-0459